Navigation Links
Dilon Technologies Signs Amerinet for Breast-Specific Gamma Imaging
Date:7/16/2008

ovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a high-resolution, small field-of-view gamma camera, optimized to perform Breast-Specific Gamma Imaging (BSGI), a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. For more information on Dilon Technologies please visit http://www.dilon.com.


'/>"/>
SOURCE Dilon Technologies
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Dilon Technologies Announces National Agreement with MedAssets
2. Settlement Reached Between Dilon Technologies and Naviscan on Patent Rights
3. Dilon Technologies Appoints New VP of Sales & Business Development
4. Dilon Technologies Explores Improvements in Molecular Breast Imaging
5. Wound Management Technologies, Inc. Announces Filing of a 510K
6. Alta Bates Medical Group (ABMG) Teams With Illumisys, LLC to Promote Quality of Care to Patients and Increase Adoption and Use of Health Information Technologies.
7. Althea Technologies Appoints E.J. Brandreth to Vice President of Quality and Regulatory
8. Netsmart Technologies Web Seminar Helps Behavioral Health Organizations Understand Electronic Prescribing And The Importance Of New Medicare-Related E-Prescribing Legislation
9. VNUS Medical Technologies to Report Second-Quarter 2008 Results and Webcast Teleconference on July 29
10. Cadient Groups GEL Interactive Technologies Celebrates Major Milestones for Immerse Exhibit Platform: 500th Exhibit Implementation and 250,000th Healthcare Professional Registered with Immerse Exhibit Platform
11. VNUS Medical Technologies, Inc. Announces Board of Director Resignation
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 2Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 3Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 4Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 5Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 2Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 3Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 4Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 5Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 6